A

Axia Discovery

“AI-driven accelerated development of targeted peptide therapeutics for precision oncology”

BiotechPre-SeedRaising $2.0M

Open round — Axia Discovery is raising $2.0M for its Pre-Seed

The founder is taking investor conversations now, and on PitchSpark you reach them directly — no warm intro, no gatekeeper.

Axia Discovery hero
02

Overview

Axia Discovery is a preclinical biotechnology company that utilizes an integrated platform combining physics-based molecular simulation, generative AI, and multi-omics data to identify and validate novel drug candidates. The company focuses on designing novel cyclic-peptide sequences and small molecules for hard receptor targets, specifically in areas such as oncology radioligand therapy (RLT), CNS, cardiometabolic, and renal disease. Their approach emphasizes 'in silico' design followed by rigorous wet-lab validation through CRO and academic partners.

03

Traction

as reported by the founder

21 U.S. provisional patent applications filed in 2026, 80% in-vitro hit rate

04

Pitch deck

The founder has published a deck

Sign in free to read it and request data-room access.

What problem are you solving?

Traditional drug discovery is slow, expensive, and prone to high failure rates, with 90% of clinical candidates failing to reach patients. Axia Discovery aims to reduce these failure rates and compress the 10-15 year traditional discovery timeline.

What is your moat?

The company possesses a multi-asset estate of 21 U.S. provisional patent applications (as of 2026) and utilizes a capital-light model that integrates computational design with rigorous wet-lab validation.

What is your market size?

The company notes the average cost per approved drug is $2.6B and the traditional discovery timeline is 10-15 years.

Who are your competitors?

Other AI drug discovery companies are focusing on small molecules or antibodies, not peptides

What makes your product special?

The platform pairs physics-based molecular simulation with generative AI to design novel, ownable targeting ligands. It features 'selectivity by design' to discriminate intended targets from receptor relatives and performs early computational assessment of PK, safety, and developability liabilities.

What is your revenue model?

The company pursues co-development partnerships and licensing opportunities for its pipeline and computational platform.

06

Founding team

VZ

Valentin Zhigulin

Founder and CSO

Dr. Valentin Zhigulin leads quantitative research and machine-learning-driven strategies. He has a background in institutional finance and is focused on designing novel therapeutics for hard receptor targets.

07

Investor activity

from real engagement records

An investor engaged with this pitch

3 days ago

An investor engaged with this pitch

8 days ago

An investor engaged with this pitch

8 days ago

5 investors reviewed this pitch

last 30 days

Investor identities are never shown.

10

Company updates

No updates posted yet.

Follow this company

Get an email when Axia Discovery posts an update. No account needed — one click to unsubscribe.

Axia Discovery — raising $2.0M